NeuroSense Therapeutics is currently facing de-listing from the Nadaq, so encouraging data from a phase 2b trial of its PrimeC drug candidate for amyotrophic lateral sclerosis (ALS) comes at an opportune time.The results suggest that PrimeC – a novel formulation of well-established drugs ciprofloxacin and celecoxib – was able to slow progression by 36% measured by the ALSFRS-R scale compared to the placebo after 12 months, while survival was improved by 43%.
